title: The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
abstract: BACKGROUND
  A limited number of studies have been conducted on the effects of hormonal therapy with tamoxifen (TMX) or aromatase inhibitors (AIs) on plasma levels of leptin and adiponectin, as well as body composition in breast cancer (BC) patients. Therefore, we aimed to analyze the relationship between adipocytokines and body composition as well as the effects of TMX and AIs on plasma adiponectin, leptin, leptin/adiponectin ratio (LAR) and body composition.
  
  
  METHODS
  Patients were treated with either TMX or AI according to their menopausal status after adjuvant radiotherapy. Changes in body composition and serum leptin and adiponectin levels were evaluated. We recorded the type of hormonal therapy, BMI, waist/hip ratio (WHR), leptin and adiponectin levels at study entry, and after 6 and 12 months.
  
  
  RESULTS
  From baseline to the 6- and 12-month follow-ups, there were statistically significant increases in WHR (p = 0.003), fat mass (p = 0.041), and serum leptin (p < 0.001) and adiponectin levels (p < 0.001). The changes in body composition and serum leptin and adiponectin levels were similar in TMX and AI groups. A statistically significant decrease was found in total body water and LAR (p < 0.001). Although weight and body fat percentage increased, such increases were not statistically significant. A positive correlation was found between baseline BMI and serum leptin levels. This correlation was maintained at 6 and 12 months. The negative correlation found between serum adiponectin levels at baseline and baseline BMI did not last throughout the study.
  
  
  CONCLUSIONS
  In this study, increased leptin and adiponectin levels and a decreased LAR were found in both AI and TMX groups. These changes might have occurred through both mechanisms of hormonal therapy and body composition changes. Therefore, AIs and TMX may exert their protective effects for BC patients by decreasing LAR rather than affecting leptin or adiponectin alone.
authors.forename: Murat
authors.initials: M
authors.lastname: Akyol
authors.forename: Leyla
authors.initials: L
authors.lastname: Demir
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alacacioglu
authors.forename: Hülya
authors.initials: H
authors.lastname: Ellidokuz
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Kucukzeybek
authors.forename: Yasar
authors.initials: Y
authors.lastname: Yildiz
authors.forename: Zehra
authors.initials: Z
authors.lastname: Gumus
authors.forename: Vedat
authors.initials: V
authors.lastname: Bayoglu
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Yildiz
authors.forename: Tarık
authors.initials: T
authors.lastname: Salman
authors.forename: Umut
authors.initials: U
authors.lastname: Varol
authors.forename: Betul
authors.initials: B
authors.lastname: Kucukzeybek
authors.forename: Lutfiye
authors.initials: L
authors.lastname: Demir
authors.forename: Ahmet
authors.initials: A
authors.lastname: Dirican
authors.forename: Recep
authors.initials: R
authors.lastname: Sutcu
authors.forename: Mustafa Oktay
authors.initials: MO
authors.lastname: Tarhan
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects*; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020738:Leptin / Q000097:blood*; D000077289:Letrozole; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020738:Leptin; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077289:Letrozole